Contribution ID: 60087a99-ce26-4230-b0d1-f35c5bafecd3

Date: 03/03/2020 15:09:12

Fitness Check of EU legislation with regard to Endocrine Disruptors - Public Consultation

Fields marked with *	ara mandatary	
Fields marked with *	are manualory.	

Introduction

Scope and objectives

Endocrine disruptors are chemical substances that interfere with hormones (the endocrine system) and in doing so negatively affect the health of humans and animals. They may either be synthetic or of natural origin. Exposure to endocrine disruptors can occur from different sources, such as from residues of pesticides in our food or from other types of products used or present in our daily life.

On 7 November 2018, the EU Commission, in its communication "Towards a comprehensive European Union framework on endocrine disruptors", confirmed its commitment to protect EU citizens and the environment from endocrine disruptors, by minimising human and wildlife exposure to these substances. The Communication outlines a comprehensive set of actions including a cross-cutting **Fitness Check** of the relevant legislation.

EU legislation regulating chemicals has been developed at different points in time and has, in certain cases, different objectives. This has resulted in different approaches to regulating endocrine disruptors, depending on the sector, and has raised questions as to whether the EU legal framework regulating endocrine disruptors is sufficiently coherent. The Fitness Check aims at analysing the coherence of the different regulatory approaches to the assessment and management of endocrine disruptors and at assessing whether the current legislation delivers on its objectives to protect human health and the environment. The outcome of the Fitness Check will inform potential improvements of the regulatory framework with regard to endocrine disruptors. More information is available in the published Roadmap. Stakeholder consultation is an essential component of the Fitness Check. It aims at gathering inputs from a broad range of stakeholder groups as well as citizens to ensure that views from all interested parties are considered in the evaluation.

The aims of this public survey are:

- To assess public concerns and needs with respect to endocrine disruptors in the EU.
- To evaluate to which extent current EU legislation meets the concerns and needs of citizen.
- To identify opportunities for improvement in the way endocrine disruptors are assessed, managed and potential risks communicated.

Target audience

This survey targets the general public, i.e. **individuals in their own capacity**. The survey is designed from the perspective of a citizen. It does not assume previous experience or specific knowledge on regulatory

risk assessment and management of endocrine disruptors.

If you would like to comment on behalf of an organisation please reply to the <u>Stakeholders Survey</u>. The Stakeholders Survey is open from 06/12/2019 to 31/01/2020.

About you

- *Language of my contribution
 - Bulgarian
 - Croatian
 - Czech
 - Danish
 - Dutch
 - English
 - Estonian
 - Finnish
 - French
 - Gaelic
 - German
 - Greek
 - Hungarian
 - Italian
 - Latvian
 - Lithuanian
 - Maltese
 - Polish
 - Portuguese
 - Romanian
 - Slovak
 - Slovenian
 - Spanish
 - Swedish
- *I am giving my contribution as
 - Academic/research institution
 - Business association
 - Company/business organisation
 - Consumer organisation
 - EU citizen
 - Environmental organisation
 - Non-EU citizen
 - Non-governmental organisation (NGO)
 - Public authority
 - Trade union
 - Other
- * First name

Elisabeth			
*Surname			
RUFFINENGO			
+ Email (this wan't ha	oublished)		
* Email (this won't be p	•		
elisabeth.ruffinengo@w	veci.eu		
*Organisation name			
255 character(s) maximum	7		
Women Engage for a C	Common Future		
 Large (250 or n Transparency register 255 character(s) maximum 	employees) 249 employees) nore) er number	oluntary database for organisations	seeking to influence EU decision-
*Country of origin			
Please add your country of original			
Afghanistan Ålandlalande	Djibouti	Libya	Saint Martin
Åland Islands	Dominica	Liechtenstein	Saint Pierre and Miquelon
Albania	Dominican Republic	Lithuania	Saint Vincent and the Grenadines
Algeria	Ecuador	Luxembourg	Samoa
American	Egypt	Macau	San Marino
Samoa	□ Cl Colvedor	Madagaaar	Cão Tomá and
Andorra	El Salvador	Madagascar	São Tomé and Príncipe
Angola	Equatorial Guinea	Malawi	Saudi Arabia
Anguilla	Eritrea	Malaysia	Senegal
Antarctica	Estonia	Maldives	Serbia
Antigua and Barbuda	Eswatini	Mali	Seychelles

ArgentinaArmenia	EthiopiaFalkland Islands	MaltaMarshallIslands	Sierra LeoneSingapore
Aruba	Faroe Islands	Martinique	Sint Maarten
Australia	Fiji	Mauritania	Slovakia
Austria	Finland	Mauritius	Slovenia
Azerbaijan	France	Mayotte	Solomon
			Islands
Bahamas	French Guiana	Mexico	Somalia
Bahrain	French	Micronesia	South Africa
	Polynesia		
Bangladesh	French Southern and Antarctic Lands	Moldova	South Georgia and the South Sandwich Islands
Barbados	Gabon	Monaco	South Korea
Belarus	Georgia	Mongolia	South Sudan
Belgium	Germany	Montenegro	Spain
Belize	Ghana	Montserrat	Sri Lanka
Benin	Gibraltar	Morocco	Sudan
Bermuda	Greece	Mozambique	Suriname
Bhutan	Greenland	Myanmar /Burma	Svalbard and Jan Mayen
Bolivia	Grenada	Namibia	Sweden
Bonaire Saint Eustatius and Saba	Guadeloupe	Nauru	Switzerland
Bosnia and Herzegovina	Guam	Nepal	Syria
Botswana	Guatemala	Netherlands	Taiwan
Bouvet Island	Guernsey	New Caledonia	Tajikistan
Brazil	Guinea	New Zealand	Tanzania
British IndianOcean Territory	Guinea-Bissau	Nicaragua	Thailand
British Virgin	Guyana	Niger	The Gambia
Islands	•	J	
Brunei	Haiti	Nigeria	Timor-Leste
Bulgaria	Heard Island	Niue	Togo
	and McDonald		
- B 1: E	Islands		- T
Burkina Faso	Honduras	Norfolk Island	Tokelau
Burundi	Hong Kong	Northern	Tonga
Cambodia	■ Hungary	Mariana Islands North Korea	Trinidad and
- Calliboula	Hungary	- North Norta	Tobago
Cameroon	Iceland	North	Tunisia
	 	Macedonia	- ········
Canada	India	Norway	Turkey

IndonesiaIran	OmanPakistan	TurkmenistanTurks and Caicos Islands
Iraq	Palau	Tuvalu
Ireland	Palestine	Uganda
Isle of Man	Panama	Ukraine
Israel	Papua New Guinea	United Arab Emirates
Italy	Paraguay	UnitedKingdom
.lamaica	Peru	United States
Japan	Philippines	United StatesMinor OutlyingIslands
Jersey	Pitcairn Islands	Uruguay
Jordan	Poland	US Virgin
		Islands
Kazakhstan	Portugal	Uzbekistan
Kenya	Puerto Rico	Vanuatu
Kiribati	Qatar	Vatican City
Kosovo	Réunion	Venezuela
Kuwait	Romania	Vietnam
Kyrgyzstan	Russia	Wallis and
		Futuna
Laos	Rwanda	Western
		Sahara
Latvia		Yemen
		7 Zambia
Lebanon	Ascension and Tristan da Cunha	Zambia
Lesotho	Saint Kitts and Nevis	Zimbabwe
Liberia	Saint Lucia	
	 Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho 	Iran Pakistan Iraq Palau Ireland Palestine Isle of Man Panama Israel Papua New Guinea Paraguay Jamaica Peru Japan Philippines Jersey Pitcairn Islands Poland Kazakhstan Portugal Kenya Puerto Rico Kiribati Qatar Kosovo Réunion Kuwait Romania Kyrgyzstan Russia Laos Rwanda Latvia Saint Barthélemy Saint Helena Ascension and Tristan da Cunha Saint Kitts and Nevis

Publication privacy settings

The Commission will publish the responses to this public consultation. You can choose whether you would like your details to be made public or to remain anonymous.

Anonymous

Only your type of respondent, country of origin and contribution will be published. All other personal details (name, organisation name and size, transparency register number) will not be published.

Public

Your personal details (name, organisation name and size, transparency register number, country of origin) will be published with your contribution.

■ I agree with the personal data protection provisions
Information on endocrine disruptors
 1) How well informed are you about endocrine disruptors? Very well informed Reasonably well informed Poorly informed Not informed at all
 2) Where do you get information about endocrine disruptors from? More than one answer is possible. ✓ European Commission and EU agencies ✓ National authorities in your country ☐ Specialised scientific sources ☐ Education and training sources ☐ General news coverage ☐ Social media ✓ Other sources (please specify below) ☐ I do not look for information on endocrine disruptors
Other sources:
consumer magazines and consumer products surveys
3) How well informed are you about the decisions made in the EU with regard to endocrine disruptors? One Not at all, I trust regulators to make the right decisions to keep me safe. Somewhat informed. Very well informed. Don't know.
 4) Do you think that the effects of endocrine disruptors on public health and the environment are understood? Yes

- Yes, to some extent
- No
- Don't know

Effectiveness of EU laws

5) In your opinion, to which extent do EU laws protect you from exposure to endocrine disruptors through:

	Not al all	To a small extent	To a moderate extent	Fully	Don't know
Outdoor air	•	0	0	0	0
Drinking water (tap water)	•	0	0	0	0
Home or office (e.g. furnishing, flooring, paints)	•	0	0	0	0
Food and beverages	0	•	0	0	0
Food contact materials including packaging (e. g. plastic films, pizza boxes)	0	•	0	0	0
Detergents	•	0	0	0	0
Medicines	•	0	0	0	0
Medical devices (e.g. prostheses, stents, bandages, dental fillings)	•	0	0	0	0
Personal care products (e.g. cosmetics, personal hygiene)	0	•	©	©	0
Electric and electronic equipment	•	0	0	0	0
Clothes	•	0	0	0	0
Others (please specify)	•	0	0	0	0

Other

50 character(s) maximum

other fields are totally ignored

- 6) In your opinion, how well do EU laws protect you from endocrine disruptors compared to other toxic chemicals (e.g. carcinogenic or mutagenic substances, substances toxic to reproduction)?
 - I am less protected from endocrine disruptors
 - I am protected from endocrine disruptors and other toxic chemicals to the same extent
 - I am less protected from other toxic chemicals
 - Don't know
- 7) The endocrine (hormonal) system controls a large number of processes in the body throughout life from early stages such as embryonic development and puberty, to later ones such as reproductive life and old age. Considering different life stages, in your opinion how well do EU laws protect citizens from effects of endocrine disruptors?

	High level of protection	Moderate level of protection	Low level of protection	Don't know
Unborn through exposure during pregnancy	0	•	0	0
Newborn up to the age of 3	0	•	0	0
Children until puberty	0	•	0	0
Adolescents	0	0	0	0
Pregnant women	0	•	0	0
Adults in general	0	0	•	0
People at work	0	0	•	0
Elderly	0	0	•	0
People with illnesses	0	0	•	0

- 8) In your opinion, to what extent are endocrine disruptors contributing to some human diseases/health conditions such as infertility, cancer or obesity?
 - Not at all
 - To a small extent
 - To a moderate extent
 - To a large extent
 - Don't know
- 9) In your opinion, how well does EU legislation protect the following categories of wildlife from effects of endocrine disruptors?

	High level of protection	Moderate level of protection	Low level of protection	Don't know
Insects, including bees and other pollinators	0	0	•	0
Other invertebrates, such as snails, shrimps and worms	0	0	•	0
Fish and amphibians	0	0	•	0
Birds and reptiles	0	0	•	0
Mammals	0	0	•	0
Plants	0	0	•	0

A common goal of EU laws on chemicals is the protection of human health and the environment. This should be achieved through minimising exposure to hazardous chemicals. At the same time EU laws have the goal to improve the free movement of goods in the EU.

Chemicals are managed under different EU laws according to their uses. Some EU laws require specific

assessment of endocrine disrupting properties of the chemicals. Others do not specifically refer to endocrine disruptors but may have links to those laws. Depending on the sector this has resulted in different approaches to endocrine disruptors. This has raised the question as to whether the EU laws are sufficiently coherent with regard to endocrine disruptors.

10) In your opinion, should the EU have the same approach across regulatory sectors (e.g. industrial chemicals, cosmetics, plant protection products, biocides, food) to:

	Yes, the same approach should be applied to all sectors	Yes, to the extent possible	No, the approach should be sector specific	Don't know
Identifying endocrine disruptors	•	©	0	0
Managing the risks of exposure to endocrine disruptors	©	•	0	0

11) In your opinion, to which extent do EU laws allow for **identification** of endocrine disruptors in the following sectors?

	Endocrine disruptors are all identified	Endocrine disruptors are partially identified	Few are identified	None are identified	Don't know
Pesticides	0	•	0	0	0
Biocides	©	•	0	0	0
Toys	©	0	•	0	0
Detergents	©	0	0	•	0
Fertilisers	©	0	0	0	•
Electrical and electronic equipment	0	0	0	•	0
Furnishings (home /office)	0	0	0	•	0
Food contact materials	0	0	0	•	0
Food additives	0	0	•	0	0
Personal care products	0	0	•	0	0
Medical devices	0	0	0	•	0

Human and veterinary	0	0	•	0	0
medicines					

12) In your opinion, to which extent do EU laws **manage the risks** to endocrine disruptors in the following sectors?

	Well managed	Fairly well managed	Not well managed	Don't know
Pesticides	0	0	•	0
Biocides	0	0	•	0
Toys	0	0	•	0
Detergents	0	0	•	0
Fertilisers	0	0	•	0
Electrical and electronic equipment	0	©	•	0
Furnishings (home/office)	0	0	•	0
Food contact materials	0	0	•	0
Food additives	0	0	•	0
Personal care products	0	0	•	0
Medical devices	0	0	•	0
Human and veterinary medicines	0	©	•	0

Regulatory testing and animal welfare

EU laws on biocides and pesticides and on chemicals (REACH) require testing for endocrine disrupting properties of a substance. They also specifically ask to minimise the use of vertebrate animals (in accordance with EU laws on the protection of animals used for scientific purposes).

- 13) In your opinion, when testing chemicals for endocrine disrupting properties, is the animal testing minimised in the EU?
 - Not at all
 - Insufficiently minimised
 - Minimised to the extent possible
 - Fully minimised
 - Don't know

Efficiency of EU laws

Benefits of EU laws include protection of human health and the environment and the free movement of goods in the EU market. Costs can be economic (time, resources) as well as ethical (e.g. use of laboratory animals for testing). Efficiency considers the benefits in relation to costs.

- 14) In your view, are the costs (e.g. time, resources, use of laboratory animals) of the EU laws on endocrine disruptors justified and proportionate for the benefits accrued?
 - Not at all
 - To a small extent only
 - To a moderate extent
 - Fully
 - Don't know
- 15) In your opinion, to which extent do EU laws on endocrine disruptors generate:

	Not al all	To a small extent only	To a moderate extent	Fully	Don't know
Costs for the agricultural sector	0	0	•	0	0
Costs for the industry sector	0	0	•	0	0
Costs for citizens	•	0	0	0	0
Ethical costs	•	0	0	0	0
Other (please specify)	0	0	0	0	0

16) In your opinion, to which extent do EU laws on endocrine disruptors generate benefits for:

	Not al all	To a small extent only	To a moderate extent	Fully	Don't know
Human health	0	0	0	•	0
Wildlife	0	0	0	•	0
EU market	0	0	0	•	0

- 17) In your opinion, who should regulate to protect people and wildlife from harm caused by endocrine disruptors? (multiple answers possible)
 - Local/regional authorities
 - National authorities
 - EU authorities
 - International organisations
 - There is no need to take measures
 - Don't know

18) In which areas do you see the need for the EU to step up its efforts on endocrine disruptors?

	A lot of efforts are needed	Some efforts are needed	The efforts are sufficient	Don't know
Identification of endocrine disruptors	•	0	0	0
Coherent approach to identification and management of endocrine disruptors across regulatory sectors	•	0	0	0
Reducing exposure of humans	•	0	0	0
Reducing exposure of wildlife	•	0	0	0
Reduction of burdens and costs to business	0	0	•	0

Open question

19) Please provide any additional comment or suggestio	n that you consider
relevant for the endocrine disruptors Fitness Check.	

2	2000 character(s) maximum						

Please upload your file

The maximum file size is 1 MB Only files of the type pdf,txt,doc,docx,odt,rtf are allowed

Thank you for your participation!

Contact

JRC-F3-ENQUIRIES@ec.europa.eu